Growth factor peptide (IGF-1 splice-variant related)

MGF (Mechano Growth Factor)

MGF is a name for an IGF-1 splice-variant product; the app lists a half-life of about 6 minutes (0.1 h), and the sources cited here report no half-life for it.

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

MGF (Mechano Growth Factor) after one dose: 50% at ~6 min, 25% at 12 min, 12.5% at 18 min.

Drawn from the half-life in the app's model, ~6 min. The model's figures

MGF (mechano growth factor) is named after an IGF-1 splice variant that is up-regulated in muscle after mechanical stress.1 The same review describes "a synthetically manufactured peptide (also termed MGF) corresponding to the 24 most C-terminal residues of IGF-IEb", which "has been shown to promote cellular proliferation and survival".1 It then adds that "no analogous peptide product of the Igf1 gene has been identified in or isolated from cultured cells, their conditioned medium, or in vivo animal tissues or biological fluids".1

The app files MGF as a growth factor peptide, lists intramuscular and subcutaneous routes, and notes that it is a splice variant of IGF-1 (the IGF-1Ec isoform). A 2026 review of performance-enhancing peptides states that "PEG-MGF is marketed as a PEGylated form of mechano-growth factor (MGF)", and that "No peer-reviewed clinical studies in humans have reported the route of administration" for it.2 A 2012 mass spectrometry report states that MGF "has not yet been approved for therapeutic use" and is "readily available on the black market".3 The app grades the evidence for MGF as emerging. No controlled trial of administered MGF in people was identified in PubMed or ClinicalTrials.gov, so the human data below describe the body's own MGF expression after exercise, not the effect of giving MGF.

The naming and the mechanism are both contested in the sources, and the findings differ by system (people, cultured cells, mice). Kandalla and colleagues (Institut de Myologie, Paris, Mechanisms of Ageing and Development, 2011) write that "MGF, also called IGF-1Ec, has a unique E domain with a 49bp insert in humans".5 In cultured human muscle cells from healthy subjects of different ages, they report that the MGF E peptide "significantly increases the proliferative life span and delays senescence of satellite cells isolated from neonatal and young adult but not from old adult muscle".5 The same paper reports that "hypertrophy associated with a significant decrease in the percentage of reserve cells was observed in all cultures".5 Geoffrey Goldspink, an author of that paper, also co-wrote a 2008 review in Current Opinion in Pharmacology saying that MGF "'kick starts' the hypertrophy process" and "has already attracted the attention of body builders".7 The PubMed records for these two papers list the work as "Research Support, Non-U.S. Gov't" and name no commercial sponsor.5,7

A 2026 review of GH-IGF-1-axis performance-enhancing peptides lists the proposed pathway of PEG-MGF as "IGF-1R tyrosine kinase signaling; satellite cell proliferation; preclinically described local role after mechanical stress/damage", with "No peer-reviewed human studies".2 The same review cautions that "biological effects observed with native IGF-1Ec or isolated E-domain peptides cannot be assumed to apply to PEG-conjugated constructs".2

Deeper analysis: Fornaro and colleagues, cultured muscle cells, 2014

Fornaro and colleagues (Novartis Institutes for Biomedical Research, Basel, and a second company, American Journal of Physiology Endocrinology and Metabolism, 2014) tried to repeat the reported effects of MGF peptides in cells.6 The design was in vitro only: C2C12 mouse cells, primary human skeletal muscle myoblasts and primary mouse muscle stem cells for proliferation and differentiation, and cardiac myocytes for p-ERK or p-Akt activation.6 The authors report that "Concentrations of peptide up to 500 ng/ml failed to increase the proliferation of C2C12 cells or primary human skeletal muscle myoblasts", whereas "all cell types exhibited a proliferative response to mature IGF-1 or full-length IGF-1Eb".6 They also report no activating response from "the native or a stabilized MGF peptide".6 The authors conclude that "These results call in to question whether there is a physiological role for MGF".6 The PubMed record for this paper gives no funding statement and no limitations paragraph beyond the conclusion above; the first author is affiliated with Novartis, and the authors describe the work as done at two pharmaceutical companies.6

Deeper analysis: Liu and colleagues, mouse muscle injury, 2019

Liu and colleagues (School of Kinesiology, Shanghai University of Sport, Frontiers in Physiology, 2019) injected MGF peptide into injured muscle of mice.8 The study used "One hundred fifty-four C57BL/6J mice" in three groups (contusion, contusion plus macrophage depletion, and contusion plus macrophage depletion plus MGF), with n = 8 in most reported figures, n = 4 for the regenerating myofibre measures and n = 3 for the fibrosis area.8 MGF peptide was injected into each injured muscle "immediately and at 1 and 2 days after muscle injury", at 5 μg per injection, and control mice received buffer.8 The main result was mixed: "injection of MGF did not exert a protective effect on muscle fiber regeneration; however, it did decrease fibrosis in the contused skeletal muscle after macrophage depletion".8 The same paper also reports that "MGF injection decreased the expression of muscle inflammatory cytokines (TNF-α, IFN-γ, IL-1β, and TGF-β), chemokines (CCL2, CCL5, and CXCR4), oxidative stress factors (gp91phox)" (mRNA measures in injured mouse muscle).8 The Discussion adds that MGF injection "did not influence the expression of MyoD and myogenin in the injured skeletal muscle after macrophage depletion", so the authors conclude the fibrosis effect was not through satellite cell status.8 The funding statement lists the National Natural Science Foundation of China, the Natural Science Foundation of Shanghai and the Key Lab of Development and Protection of Human Sports Ability in Shanghai, and the authors declare no commercial or financial relationships.8 The full text has no limitations paragraph, and the model (macrophage-depleted mice with a contusion) is not a model of healthy people.8

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~6 min
Bioavailability
70%
Typical dose
100–300 mcg/day
Route
IM, SubQ
Time to peak
~6 min

The app lists a half-life of about 6 minutes (0.1 h), a time to peak of about 6 minutes (0.1 h), a duration of about 0.5 h, 70% bioavailability and a one-compartment model; none of the sources cited here reports a measured value for any of these in people. The app's note describes the half-life as "~5–7 minutes" because of rapid proteolytic degradation; the sources here neither confirm nor contradict that figure.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~6 min (0.1 h)Not reported for PEG-MGF in the 2026 review ("t½ not reported"); no human measurement for native MGF was identified2
Time to peak~6 min (0.1 h)Not reported in the sources cited here
Bioavailability70%Not reported in the sources cited here; the 2026 review says no peer-reviewed human clinical study has reported the route of administration for PEG-MGF2
Duration~0.5 hNot reported in the sources cited here
RoutesIM, SubQRoute not reported in human clinical studies of PEG-MGF2

For a variant sold as MGF R23H in confiscated vials, Cox and colleagues (Sports Medicine Research and Testing Laboratory, Salt Lake City, Drug Testing and Analysis, 2017) report that "In vitro metabolism experiments in plasma demonstrate that MGF R23H has good stability".9 That is a laboratory plasma experiment on one variant, not a measurement in people, and it is not a half-life.9 The 2026 review states that "pegylation extends stability" for PEG-MGF, with "t½ not reported".2

None of the sources cited here reports an interval for MGF levels, so the page has no level chart.

4

Human studies

No trial of administered MGF in people was identified; the two human studies below measured the body's own MGF mRNA in muscle biopsies after exercise.4,10

Table 4.1Human studies2 rows
Study and yearDesignPeopleDose and lengthMain result
Philippou and colleagues, In Vivo, 20094Exercise-induced muscle damage with biopsies; plus cell experiments with synthetic MGF E peptide10 healthy male volunteersNo MGF given; biopsies before and 6 h, 2, 5 and 16 days after exerciseMGF mRNA showed a "rapid and transient up-regulation", followed by a prolonged rise in IGF-1Ea and IGF-1Eb mRNA4
Roberts and colleagues, European Journal of Applied Physiology, 201010Three sequential resistance workouts with vastus lateralis biopsies10 males aged 18-25 and 10 males aged 60-75No MGF given; three workouts (Monday, Wednesday, Friday) of nine sets of ten repetitions at 80% of one repetition maximum, biopsies at four time pointsMGF expression "increased at T2-T4 in the older group relative to baseline values"; muscle IGF-1EA mRNA and IGF-1 peptides "remained stably expressed" in both age groups10

Deeper analysis: Philippou and colleagues, muscle damage in healthy men, 2009

Philippou and colleagues (Department of Experimental Physiology, National and Kapodistrian University of Athens, In Vivo, 2009) took muscle biopsies from 10 healthy male volunteers before and 6 h, 2, 5 and 16 days after exercise-induced muscle damage.4 They report "a rapid and transient up-regulation of MGF mRNA expression which was followed by a prolonged increase of IGF-1Ea and IGF-1Eb mRNA expression", with similar patterns for MGF and IGF-1Ea protein.4 In the cell part of the study, the synthetic MGF E peptide's effect on C2C12 myoblast-like cells "was not blocked by an anti-IGF-1 receptor neutralizing antibody and it did not phosphorylate Akt".4 The authors conclude that MGF and mature IGF-1 products "possibly act as distinct mitogens in skeletal muscle regeneration".4 The result is in 10 men with no comparison group, nothing was given to the participants, and the PubMed record states no funding and no limitations.4

Deeper analysis: Roberts and colleagues, young and older men, 2010

Roberts and colleagues (University of Oklahoma, European Journal of Applied Physiology, 2010) compared 10 younger and 10 older men over three resistance workouts.10 They report "no baseline differences in MGF or IGF-1EA mRNA expression and IGF-1 peptides between age groups", and an MGF increase only in the older group.10 They note this "is contrary to previous research examining this gene at different post-exercise time points, albeit the physiological consequences of these findings remain unknown".10 The PubMed record labels the paper "Research Support, Non-U.S. Gov't", and lists no limitations paragraph.10

5

Doses reported in studies and on labels

No MGF label was identified in DailyMed and no trial of administered MGF was identified, so no label or trial dose is given. The table lists the app's range, a 2026 review's summary of online forum reports for PEG-MGF, and the single dose schedule in the mouse study.

Table 5.1Doses reported in studies and on labels3 rows
SourceProduct, species and routeDose reportedStatus of the figure
The appMGF, IM or SubQ100–300 mcg/dayThe app's figure; not reported in the sources cited here
Dominikowski and colleagues, 20262PEG-MGF, SC or IM, from bodybuilding-related forums200–400 µg, 2–3 times a week after exercise; loading protocol 100 µg for 2 weeks, 200 µg for 2 weeks, 300 µg for 4 weeks; maintenance 200–400 µg/day; typical cycles of 8–16 weeks with about a 4-week washoutOnline reports, described by the review as "often internally inconsistent online protocols"; not from a trial2
Liu and colleagues, 20198MGF peptide, injected into injured muscle of mice5 μg per injection, at injury and 1 and 2 days laterAnimal study; n = 8 in most reported figures, n = 4 for regenerating myofibres and n = 3 for fibrosis area8
6

Side effects reported

Sources in this part

  1. 2Dominikowski et al., 2026

No human study of administered MGF reporting adverse events was identified, so there is no adverse event rate to give. The 2026 review lists a "Theoretical proliferative concern based on IGF-1Ec (MGF) expression in cancer biology (preclinical evidence)" for PEG-MGF.2 For the group of peptides it covers, which includes PEG-MGF, the same review reports adverse effects spanning "endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetite changes, and dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions".2 Those effects are described for the group as a whole; the review's own table records "no human data for PEG-MGF" on GH or IGF-1 overactivation.2

7

Bloodwork and markers

The app lists IGF-1 as the marker to monitor for MGF. The 2026 review states that "IGF-1 analogues are expected to reproduce core IGF-1 biological actions (to varying degrees depending on formulation, bioavailability, and exposure profile)", which is its reasoning for IGF-1-axis monitoring; it reports no human measurement for PEG-MGF.2 In the Roberts study, "total muscle IGF-1 peptides" were assayed by ELISA in muscle biopsies, not in blood.10

The World Anti-Doping Agency 2026 Prohibited List names "Mechano growth factors (MGFs)" under S2.3, growth factors and growth factor modulators.12 Class S2 is headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and the list says the substances named are examples ("Including, but not limited to").12 Thevis and colleagues (Growth Hormone and IGF Research, 2014) write that the MGF peptide, "the substance (or class of substances) has been considered prohibited according to the regulations of the World Anti-Doping Agency (WADA) since 2005".11 They characterised a product sold as "full-length MGF" with a monoisotopic mass of 12264.9 Da, a terminal lysine eliminated and an R109H substitution, and detected it at 0.25 ng/mL with immunoaffinity purification and mass spectrometry.11 They add that "Future tests are indicated probing for optimized/dedicated detection methods and assessment of efficacy and elimination kinetics of the substance".11 Esposito and colleagues (Ghent University Doping Control Laboratory, 2012) identified "a MGF C-terminal amidated analogue in two black market products".3 Cox and colleagues report a variant, MGF R23H, in confiscated vials.9 No label for MGF was identified in DailyMed.

Whether administered MGF reaches or acts on muscle in people is not shown by any source cited here. Whether the MGF E peptide exists as a natural product is itself questioned: Matheny and colleagues state that no analogous peptide product of the Igf1 gene has been identified in cells, medium or animal tissues and fluids, and Fornaro and colleagues question "whether there is a physiological role for MGF".1,6 Kandalla and colleagues and Philippou and colleagues report cell effects of the E peptide, and Fornaro and colleagues did not reproduce such effects, so the cell evidence points both ways.5,4,6 The half-life, time to peak, bioavailability and dose of MGF in people are not reported in the sources cited here, and the Roberts authors note that the "physiological consequences" of changes in MGF expression "remain unknown".10

What is the half-life of MGF?

The app lists about 6 minutes (0.1 h), and none of the sources cited here reports a half-life for MGF.2 The 2026 review gives "t½ not reported" for the PEGylated form.2

Is MGF banned by WADA?

Yes, the WADA 2026 Prohibited List names "Mechano growth factors (MGFs)" under S2.3.12 Class S2 is prohibited in and out of competition.12

Is MGF approved as a medicine?

A 2012 report states that MGF "has not yet been approved for therapeutic use", and no label for it was identified in DailyMed.3

What is MGF?

MGF is the name given to an IGF-1 splice variant up-regulated in muscle after mechanical stress, and to a 24-residue peptide from its C-terminal region.1

Is MGF the same as IGF-1?

Kandalla and colleagues describe MGF (IGF-1Ec) as a member of the IGF-1 super family with "a unique E domain with a 49bp insert in humans".5 Philippou and colleagues report that the MGF E peptide's effect on myoblast-like cells was not blocked by an anti-IGF-1 receptor antibody, unlike mature IGF-1 effects in the same comparison.4

Has MGF been tested in people?

No trial of administered MGF in people was identified in PubMed or ClinicalTrials.gov. Human studies identified measured the body's own MGF mRNA in muscle biopsies after exercise, in 10 men in Philippou and colleagues (2009) and 10 younger and 10 older men in Roberts and colleagues (2010).4,10

Did laboratories reproduce the cell effects of MGF peptide?

Fornaro and colleagues did not: peptide concentrations "up to 500 ng/ml failed to increase the proliferation of C2C12 cells or primary human skeletal muscle myoblasts".6 Kandalla and colleagues report that the MGF E peptide extended the proliferative life span of satellite cells from neonatal and young adult but not old adult muscle.5

What is PEG-MGF?

PEG-MGF is "marketed as a PEGylated form of mechano-growth factor (MGF)", and the 2026 review notes that "No peer-reviewed human studies" exist for it.2

12

References

  1. Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 2010. Matheny 2010
  2. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026. Dominikowski 2026
  3. Esposito S, Deventer K, Van Eenoo P. Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products. Rapid Commun Mass Spectrom 2012. PMID 22328223
  4. Philippou A, et al. Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In Vivo 2009. PMID 19567392
  5. Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev 2011. PMID 21354439
  6. Fornaro M, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab 2014. PMID 24253050
  7. Goldspink G, Wessner B, Bachl N. Growth factors, muscle function and doping. Curr Opin Pharmacol 2008. PMID 18353722
  8. Liu X, Zeng Z, Zhao L, Chen P, Xiao W. Impaired skeletal muscle regeneration induced by macrophage depletion could be partly ameliorated by MGF injection. Front Physiol 2019. PMID 31164836
  9. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal 2017. PMID 28035768
  10. Roberts MD, et al. IGF-1 splice variant and IGF-1 peptide expression patterns in young and old human skeletal muscle prior to and following sequential exercise bouts. Eur J Appl Physiol 2010. PMID 20668872
  11. Thevis M, Thomas A, Geyer H, Schänzer W. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls. Growth Horm IGF Res 2014. PMID 25466910
  12. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list